top of page
SUCCIPRO AIMS TO EXPLOIT THE SUCCINATE-METABOLIC-INFLAMMATORY AXIS TO CREATE NOVEL, FIRST-IN CLASS THERAPEUTICS FOR INFLAMMATORY AND METABOLIC DISEASES.
Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.
Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.
bottom of page